Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy
Author: ["Elizabeth S. Withers-Ward","Rafael G. Amado","Prasad S. Koka","Beth D. Jamieson","Andrew H. Kaplan","Irvin S.Y. Chen","Jerome A. Zack"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Stem cell gene therapy strategies for AIDS require that differentiation-inducing stromal elements of HIV-infected individuals remain functionally intact to support the maturation of exogenous progenitor cells into mature CD4+ cells. To investigate the feasibility of stem cell reconstitution strategies in AIDS, we used the SCID-hu mouse to examine the ability of HIV-infected CD4+ cell-depleted human thymic implants to support renewed thymopoiesis. Here we report that following treatment of these implants with antiretroviral drugs, new thymopoiesis is initiated. This suggests that antiviral therapies might allow de novo production of T lymphocytes and provides support for the concept of therapeutic strategies aimed at reconstitution of the peripheral CD4+ T-cell compartment.
Cite this article
Withers-Ward, E., Amado, R., Koka, P. et al. Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat Med 3, 1102–1109 (1997). https://doi.org/10.1038/nm1097-1102
